Tandem Diabetes Care Stock Forecast, Price & News

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Tandem Diabetes Care in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" Tandem Diabetes Care stock.
View analyst ratings for Tandem Diabetes Care or view top-rated stocks.

9 equities research analysts have issued 12 month price objectives for Tandem Diabetes Care's shares. Their TNDM stock forecasts range from $120.00 to $200.00. On average, they expect Tandem Diabetes Care's share price to reach $143.00 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price.
View analysts' price targets for Tandem Diabetes Care or view top-rated stocks among Wall Street analysts.

Tandem Diabetes Care's stock was trading at $150.52 at the beginning of the year. Since then, TNDM stock has decreased by 59.9% and is now trading at $60.34.
View the best growth stocks for 2022 here.

Tandem Diabetes Care saw a increase in short interest in June. As of June 15th, there was short interest totaling 3,900,000 shares, an increase of 18.2% from the May 31st total of 3,300,000 shares. Based on an average trading volume of 832,700 shares, the short-interest ratio is presently 4.7 days. Currently, 7.5% of the company's stock are short sold.
View Tandem Diabetes Care's Short Interest.

Tandem Diabetes Care is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022.
View our earnings forecast for Tandem Diabetes Care.

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) issued its quarterly earnings data on Wednesday, May, 4th. The medical device company reported ($0.23) earnings per share (EPS) for the quarter. The medical device company earned $175.91 million during the quarter, compared to analysts' expectations of $168.21 million. Tandem Diabetes Care had a net margin of 0.80% and a trailing twelve-month return on equity of 1.64%. The business's revenue for the quarter was up 24.7% on a year-over-year basis. During the same quarter last year, the firm earned ($0.07) EPS.
View Tandem Diabetes Care's earnings history.

Tandem Diabetes Care shares reverse split before market open on Tuesday, October 10th 2017. The 1-10 reverse split was announced on Monday, October 9th 2017. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 9th 2017. An investor that had 100 shares of Tandem Diabetes Care stock prior to the reverse split would have 10 shares after the split.

Tandem Diabetes Care issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the period. The company issued revenue guidance of $850.00 million-$865.00 million, compared to the consensus revenue estimate of $846.54 million.

11 employees have rated Tandem Diabetes Care CEO John Sheridan on Glassdoor.com. John Sheridan has an approval rating of 88% among Tandem Diabetes Care's employees.

Some companies that are related to Tandem Diabetes Care include Teleflex (TFX), Abiomed (ABMD), NovoCure (NVCR), ShockWave Medical (SWAV), Globus Medical (GMED), Inspire Medical Systems (INSP), Penumbra (PEN), Integra LifeSciences (IART), ICU Medical (ICUI), Inari Medical (NARI), iRhythm Technologies (IRTC), Haemonetics (HAE), Merit Medical Systems (MMSI), Axonics (AXNX) and NuVasive (NUVA).
View all of TNDM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Tandem Diabetes Care investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Micron Technology (MU), DexCom (DXCM), Netflix (NFLX), Square (SQ), Roku (ROKU), Lululemon Athletica (LULU) and PayPal (PYPL).

Tandem Diabetes Care trades on the NASDAQ under the ticker symbol "TNDM."

Tandem Diabetes Care's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.21%), Vanguard Group Inc. (9.86%), Capital World Investors (4.45%), Invesco Ltd. (3.25%), State Street Corp (2.67%) and Champlain Investment Partners LLC (2.41%). Company insiders that own Tandem Diabetes Care stock include Brian B Hansen, Brian B Hansen, Christopher J Twomey, Christopher J Twomey, David B Berger, Dick Allen, Douglas A Roeder, Edward L Cahill, Elizabeth Anne Gasser, Howard E Greene Jr, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, Rebecca B Robertson and Susan Morrison.
View institutional ownership trends for Tandem Diabetes Care.

TNDM stock was sold by a variety of institutional investors in the last quarter, including Capital World Investors, Sei Investments Co., RTW Investments LP, UBS Group AG, Wasatch Advisors Inc., TimesSquare Capital Management LLC, Victory Capital Management Inc., and Next Century Growth Investors LLC. Company insiders that have sold Tandem Diabetes Care company stock in the last two years include Brian B Hansen, Christopher J Twomey, David B Berger, Elizabeth Anne Gasser, James Leal, John F Sheridan, Kathleen Mcgroddy-Goetz, Kim D Blickenstaff, Leigh Vosseller, Mark Reinstra, Rebecca B Robertson, and Susan Morrison.
View insider buying and selling activity for Tandem Diabetes Care or view top insider-selling stocks.

TNDM stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Vanguard Group Inc., Invesco Ltd., Polar Asset Management Partners Inc., Atika Capital Management LLC, Bank of Montreal Can, Dimensional Fund Advisors LP, and American Century Companies Inc.. Company insiders that have bought Tandem Diabetes Care stock in the last two years include John F Sheridan, and Leigh Vosseller.
View insider buying and selling activity for Tandem Diabetes Care or or view top insider-buying stocks.

Shares of TNDM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of TNDM stock can currently be purchased for approximately $60.34.

Tandem Diabetes Care (NASDAQ:TNDM) has a market capitalization of $3.86 billion and generates $702.80 million in revenue each year. The medical device company earns $15.57 million in net income (profit) each year or $0.079990 on an earnings per share basis.

Tandem Diabetes Care employs 2,000 workers across the globe.

Tandem Diabetes Care was founded in 2006.

Tandem Diabetes Care's mailing address is 11075 ROSELLE STREET, San Diego CA, 92121. The official website for Tandem Diabetes Care is www.tandemdiabetes.com. The medical device company can be reached via phone at (858) 366-6900 or via email at [email protected].